A phase II study of VcR[bortezomib + rituximab]-hyper CVAD [cyclophosphamide + vincristine + doxorubicin + dexamethasone] with rituximab maintenance for untreated mantle cell lymphoma.

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Filgrastim; Pegfilgrastim; Rituximab; Vincristine
Indications Mantle-cell lymphoma
Focus Adverse reactions; Therapeutic Use

30 Oct 2014 Biomarkers information updated
13 Jun 2013 Planned end date changed from 1 Jul 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.
08 Mar 2012 Planned end date changed from 1 Apr 2011 to 1 Apr 2012 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com